IRLAB’s rights issue is registered – conversion of BTA into shares

IRLAB Therapeutics AB’s (the “Company”) rights issue of ordinary shares of series A, which the Board of Directors resolved on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026, is registered with the Swedish Companies Registration Office. Paid subscribed shares (“BTA”) will therefore be converted into ordinary shares of series A.

Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB

IRLAB’s rights issue was oversubscribed and the company resolves on allotment in the overallotment issue